Heidelberg Pharma AG re-affirmed earnings guidance for the fiscal year 2020. The group expects to generate between EUR 8.0 million and EUR 10.0 million in sales revenue and other income (2019: EUR 8.0 million) for the 2020 fiscal year. Loss before interest and taxes (LBIT) for the 2020 fiscal year are projected to be between EUR 11.0 million and EUR 15.0 million (LBIT of EUR 10.1 million in 2019).